Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Webcasts|April 28, 2020
Outsourcing to CROs: Expediting Clinical Operations or Oversight Nightmare?
Author(s)Oracle Health Sciences
Simply handing off multi-million-dollar studies to CROs without carefully crafted plans for communications and reporting operational data as the study unfolds is hardly a wise move, yet what kind of oversight is needed? Live: Tuesday, Apr. 28, 2020 1pm EDT | 12pm CDT | 10am PDT On demand available after airing until Apr. 28, 2021. Register free
Register free:
Event Overview:
As the complexity of clinical trials continues to increase the importance of contract research organizations (CROs) to the pharmaceutical industry has increased significantly. Outsourcing allows pharmaceutical companies to utilize on-demand services, improving operational efficiencies by accessing therapeutic expertise and geographic reach. This reflects a sharper focus on core competencies and a shift to allow CROs to manage and conduct clinical trials.
The relationship between sponsors and CROs is strengthening as outsourcing becomes a clinical trial mainstay. Yet, outsourcing of clinical trials introduces additional complexities around quality, oversight, collaboration, and governance. Communication and transparency are required to move the clinical trial forward efficiently, but how can you do this when you’re working with multiple CROs all using inconsistent reporting conventions?
Simply handing off multi-million-dollar studies to CROs without carefully crafted plans for communications and reporting operational data as the study unfolds is hardly a wise move, yet what kind of oversight is needed?
Key Learning Objectives:
In this webcast we will explore:
- What key metric components you need to define for your functional outsourcing
- How you can define quality tolerance limits for each functional area
- How Sponsors and CROs can have a common real-time view on progress and compliance without the need for micromanaging
- Limitations in current approaches to outsourcing with regards to oversight
- Why management direction is critical in efforts to jump-start overall performance optimization of vendor outsourcing
- The need to standardize and automate vendor oversight in order to drive down costs and complexities
Speakers: Andy Lawton, Consultant, Risk Based Approach Ltd
Keith Dorricott, Director, Dorricott Metrics & Process Improvement Ltd
Elvin Thalund, Director, Industry Strategy, Oracle Health Sciences
Time and date: Tuesday, Apr. 28, 2020 1pm EDT | 12pm CDT | 10am PDT
On demand available after airing until Apr. 28, 2021.
Sponsor: Oracle Health Sciences
Register free:
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5